haematology

News in Brief: VenR long term responses for relapsed CLL; High dose IVIG responses in older VITT patients; Specialists in top 10 for Australian incomes

VenR long term responses for relapsed CLL The combination of venetoclax plus rituximab (VenR) induced both a ‘deep and highly durable’ response in patients with relapsed CLL, long term follow up of a phase 1 trial reveals Five-year rates for overall survival, progression-free survival, and duration of response were 86% (95% CI, 72–94), 56% (40–70), ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic